|  | Cancer | Cancer Treatment

Understanding Immunotherapy: Harnessing Your Body's Cancer-Fighting Power

What Is Cancer Immunotherapy?

Immunotherapy (biologic therapy) treats cancer by empowering the immune system to recognize and destroy malignant cells. Unlike chemotherapy or radiation, which directly target tumors, immunotherapy enhances the body's own defenses.

Key Mechanisms

1. Immune Checkpoint Inhibition

Cancer cells exploit checkpoint proteins (PD-1, PD-L1, CTLA-4) on T cells to evade immune attack. Checkpoint inhibitors block these interactions, "releasing the brakes" on T cells.

  • Anti-PD-1/PD-L1: Pembrolizumab, nivolumab, cemiplimab, atezolizumab, durvalumab, avelumab.
  • Anti-CTLA-4: Ipilimumab.
  • Indications: Melanoma, NSCLC, RCC, urothelial, HNSCC, Hodgkin lymphoma, MSI-H/dMMR tumors, and many others.

2. Adoptive Cell Therapy (ACT)

Patient's own immune cells are collected, engineered/expanded, and reinfused.

  • CAR T-cell Therapy: T cells engineered with chimeric antigen receptors targeting CD19 (B-cell malignancies) or BCMA (multiple myeloma). Approved products: tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel, lisocabtagene maraleucel, idecabtagene vicleucel, ciltacabtagene autoleucel.
  • TIL Therapy: Tumor-infiltrating lymphocytes expanded with IL-2 (e.g., lifileucel for melanoma).

3. Cancer Vaccines

Stimulate immune response against tumor-associated antigens.

  • Preventive: HPV vaccine (cervical, anal, oropharyngeal cancers), HBV vaccine (hepatocellular carcinoma).
  • Therapeutic: Sipuleucel-T (prostate cancer), personalized neoantigen vaccines (investigational).

4. Oncolytic Viruses

Genetically modified viruses selectively replicate in and lyse cancer cells, releasing antigens and danger signals.

  • T-VEC (talimogene laherparepvec): Modified HSV-1 for injectable melanoma lesions.

5. Cytokines & Agonists

  • IL-2, IFN-α: Earlier agents with significant toxicity; now limited use.
  • STING agonists, CD40 agonists, bispecific antibodies: Emerging classes in clinical trials.

Immune-Related Adverse Events (irAEs)

Overactive immunity can attack healthy tissues: colitis, hepatitis, pneumonitis, endocrinopathies (thyroid, adrenal, diabetes), dermatitis, myocarditis, neuropathy. Early recognition and corticosteroids are key. Multidisciplinary management often needed.

Biomarkers for Response

  • PD-L1 expression (IHC)
  • Tumor mutational burden (TMB)
  • Microsatellite instability (MSI-H/dMMR)
  • Tumor-infiltrating lymphocyte (TIL) density
  • Specific mutations (e.g., KRAS G12C for some combos)

Current Landscape & Future Directions

Combination strategies (IO+IO, IO+TKI, IO+chemo, IO+radiation), neoadjuvant/adjuvant use, earlier lines of therapy, and novel targets (LAG-3, TIGIT, NK cell engagers) are expanding indications. CAR-T is moving toward solid tumors and allogeneic ("off-the-shelf") products.

Patient Considerations

  • Discuss biomarker testing with your oncologist.
  • Report new symptoms promptly (diarrhea, cough, fatigue, rash, vision changes).
  • Carry an immunotherapy wallet card for emergency providers.
  • Explore clinical trials for access to next-generation agents.

Cancer Treatment - Related Articles